Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer
Molecular Oncology · 2026-08 · 20 (8) · 2114-2128
DOI: 10.1002/1878-0261.70256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 15.04.2026. Verfasst von Yuho Ebata und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Boron Compounds, Drug Resistance, Neoplasm, Glycine, Colorectal Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge. We previously showed that camptothecin induces ubiquitin–proteasome pathway (UPP)‐mediated topoI degradation. In this study, we investigated whether inhibition of UPP could prevent topoI degradation and restore camptothecin sensitivity. SN‐38, an active metabolite of irinotecan, induced topoI degradation in irinotecan‐resistant colorectal cancer cell lines, which was suppressed by ixazomib. The combination significantly enhanced cytotoxicity, colony inhibition, and reduced IC 50 values compared with SN‐38 alone. Mechanistically, ixazomib prevented proteasome‐mediated degradation of ubiquitinated topoI, restoring its stability. In vivo, the combination significantly suppressed tumor growth in a DLD‐1 xenograft model compared with SN‐38 alone. These findings indicate that UPP‐dependent topoI degradation is a key mechanism underlying irinotecan resistance in colorectal cancer. Pharmacological inhibition of the proteasome effectively prevents topoI loss and restores irinotecan sensitivity, suggesting that proteasome inhibitors such as ixazomib may serve as promising therapeutic partners for camptothecin‐based chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Gastroenterological Surgery and Clinical Research Institute, Kyushu Medical Center, Fukuoka, Japan.
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.
- Department of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
- Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
- Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan.
ORCID-Profile: Yuho Ebata, Koji Ando
Zitieren
APA
Ebata, Y., Ando, K., Hasuda, H., Mimori, K., Unan, E. C., Pulukuri, S., Tiku, A., Berger, A., Oki, E., Bharti, A., & Yoshizumi, T. (2026). Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer. Molecular Oncology, 20(8), 2114-2128. https://doi.org/10.1002/1878-0261.70256
Vancouver
Ebata Y, Ando K, Hasuda H, Mimori K, Unan EC, Pulukuri S, et al. Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer. Molecular Oncology. 2026;20(8):2114-2128. doi:10.1002/1878-0261.70256
BibTeX
@article{Ebata2026,
author = {Ebata, Yuho and Ando, Koji and Hasuda, Hirofumi and Mimori, Koshi and Unan, Elizabeth C and Pulukuri, Siddhartha and Tiku, Aahana and Berger, Allison and Oki, Eiji and Bharti, Ajit and Yoshizumi, Tomoharu},
title = {Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {8},
pages = {2114--2128},
doi = {10.1002/1878-0261.70256}
}
EUVIMED